Regulatory T-cell specialist Dualyx NV has closed a €40 million (US$43.5 million) series A to progress the lead autoimmune disease program to the clinic and to take forward two other Treg-based therapies. The company brings together expertise in antibody design with understanding of the role Tregs play in supressing the immune response to maintain homeostasis and self-tolerance, preventing autoimmunity.
Dualyx NV has completed a €40 million (US$44 million) series A financing, allowing the company to advance its lead autoimmune program, DT-001, as well as its pipeline of regulatory T-cell (Treg) candidates.
